$AYTU
Aytu Biopharma Inc

2015 Q4 Form 10-Q Financial Statement

#000119312515370153 Filed on November 06, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q3
Revenue $469.2K $487.4K $27.58K
YoY Change 1555.95% 1666.98%
Cost Of Revenue $244.1K $37.33K $225.00
YoY Change 16488.89%
Gross Profit $225.1K $450.1K $27.36K
YoY Change 694.47% 1545.08%
Gross Profit Margin 47.98% 92.34% 99.18%
Selling, General & Admin $1.688M $1.563M $1.131M
YoY Change 125.08% 38.18% 11212.76%
% of Gross Profit 749.72% 347.33% 4135.08%
Research & Development $1.308M $855.9K $933.8K
YoY Change 65.63% -8.34%
% of Gross Profit 581.24% 190.17% 3413.09%
Depreciation & Amortization $12.00K $129.0K $24.58K
YoY Change 424.97%
% of Gross Profit 5.33% 28.67% 89.85%
Operating Expenses $3.483M $2.650M $2.065M
YoY Change 116.15% 28.35% 20550.29%
Operating Profit -$3.014M -$2.163M -$2.092M
YoY Change 90.38% 3.41%
Interest Expense $240.2K $113.3K $37.30K
YoY Change 539.77% 203.61%
% of Operating Profit
Other Income/Expense, Net -$318.4K -$113.1K -$37.30K
YoY Change 747.95% 203.27%
Pretax Income -$3.332M -$2.276M -$2.129M
YoY Change 105.61% 6.91% 21189.71%
Income Tax $0.00 $0.00 -$23.91K
% Of Pretax Income
Net Earnings -$3.332M -$2.276M -$2.105M
YoY Change 105.61% 8.13% 20950.61%
Net Earnings / Revenue -710.2% -467.02% -7631.73%
Basic Earnings Per Share
Diluted Earnings Per Share -$11.22B -$7.662B -$1.434B
COMMON SHARES
Basic Shares Outstanding 14.26M shares 14.26M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.00M $10.10M $0.00
YoY Change
Cash & Equivalents $10.96M $10.07M $1.052M
Short-Term Investments
Other Short-Term Assets $900.0K $600.0K $0.00
YoY Change
Inventory $700.0K $494.1K
Prepaid Expenses $360.5K
Receivables $300.0K $167.9K
Other Receivables $0.00 $0.00
Total Short-Term Assets $12.80M $11.31M $0.00
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $26.37K $0.00
YoY Change
Goodwill $74.00K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $300.0K $300.0K $0.00
YoY Change
Total Long-Term Assets $11.60M $10.05M $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $12.80M $11.31M $0.00
Total Long-Term Assets $11.60M $10.05M $0.00
Total Assets $24.40M $21.36M $0.00
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.100M $1.100M $0.00
YoY Change
Accrued Expenses $500.0K $600.0K $0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.800M $1.778M $100.0K
YoY Change 2700.0% 1677.89% 0.0%
LONG-TERM LIABILITIES
Long-Term Debt $4.900M $4.800M $0.00
YoY Change
Other Long-Term Liabilities $1.400M $1.300M
YoY Change
Total Long-Term Liabilities $6.300M $6.100M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.800M $1.778M $100.0K
Total Long-Term Liabilities $6.300M $6.100M $0.00
Total Liabilities $9.200M $7.951M $100.0K
YoY Change 9100.0% 7850.85% 0.0%
SHAREHOLDERS EQUITY
Retained Earnings -$20.66M
YoY Change
Common Stock $39.07M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.30M $13.41M $0.00
YoY Change
Total Liabilities & Shareholders Equity $24.40M $21.36M $0.00
YoY Change

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$3.332M -$2.276M -$2.105M
YoY Change 105.61% 8.13% 20950.61%
Depreciation, Depletion And Amortization $12.00K $129.0K $24.58K
YoY Change 424.97%
Cash From Operating Activities -$3.450M -$2.160M -$10.00K
YoY Change 34400.0% 21500.0% 0.0%
INVESTING ACTIVITIES
Capital Expenditures -$130.0K $3.554K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$540.0K
YoY Change
Cash From Investing Activities -$660.0K $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.000M 4.880M 0.000
YoY Change 24900.0% -100.0%
NET CHANGE
Cash From Operating Activities -3.450M -2.160M -10.00K
Cash From Investing Activities -660.0K 0.000 0.000
Cash From Financing Activities 5.000M 4.880M 0.000
Net Change In Cash 890.0K 2.720M -10.00K
YoY Change 8800.0% -27300.0%
FREE CASH FLOW
Cash From Operating Activities -$3.450M -$2.160M -$10.00K
Capital Expenditures -$130.0K $3.554K $0.00
Free Cash Flow -$3.320M -$2.164M -$10.00K
YoY Change 33100.0% 21535.54% 0.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
2391000
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14259693 shares
CY2015Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
102803
CY2015Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
5175000
CY2015Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
401000
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1051575
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14259681 shares
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2015Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1718828000000 shares
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14259681 shares
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q3 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
460000
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
39064689
CY2015Q3 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
691000
CY2015Q3 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
572000
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
13408586
CY2015Q3 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
575000
CY2015Q3 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
430000
CY2015Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4825310
CY2015Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
102803
CY2015Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
677153
CY2015Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1075133
CY2015Q3 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
0
CY2015Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
11379
CY2015Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
85714
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20657529
CY2015Q3 us-gaap Liabilities
Liabilities
7950846
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21359432
CY2015Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
404465
CY2015Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
5175000
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
1426
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
67000
CY2015Q3 us-gaap Contractual Obligation
ContractualObligation
2728000
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1777888
CY2015Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
94211
CY2015Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
350000
CY2015Q3 us-gaap Indefinite Lived Contractual Rights
IndefiniteLivedContractualRights
693000
CY2015Q3 us-gaap Assets
Assets
21359432
CY2015Q3 us-gaap Inventory Net
InventoryNet
494080
CY2015Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
10051672
CY2015Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
167930
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26374
CY2015Q3 us-gaap Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock
ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock
5000000
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
38996367
CY2015Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
349690
CY2015Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
4886
CY2015Q3 us-gaap Indefinite Lived Trade Names
IndefiniteLivedTradeNames
77000
CY2015Q3 us-gaap Assets Current
AssetsCurrent
11307760
CY2015Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
611079
CY2015Q3 us-gaap Goodwill
Goodwill
74000
CY2015Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
360531
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10069025
CY2015Q3 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
94211
CY2015Q3 aytu Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price
ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice
4.53
CY2015Q3 aytu Share Based Compensation Share Warrants Outstanding
ShareBasedCompensationShareWarrantsOutstanding
102613 shares
CY2015Q3 aytu Core And Developed Technology Net
CoreAndDevelopedTechnologyNet
760375
CY2015Q3 aytu Accrued Compensation Current
AccruedCompensationCurrent
617041
CY2015Q3 aytu Interest Payable Noncurrent
InterestPayableNoncurrent
57637
CY2015Q3 aytu Indefinite Lived Intangible Asset In Process Research And Development
IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment
7500000
CY2015Q3 aytu Number Of Stock Option Plans
NumberOfStockOptionPlans
2 Stock_Plan
CY2015Q3 aytu Prepaid Research And Development Related Party
PrepaidResearchAndDevelopmentRelatedParty
121983
CY2015Q3 aytu Prepaid Research And Development Related Party Noncurrent
PrepaidResearchAndDevelopmentRelatedPartyNoncurrent
304958
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2639650
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14259681 shares
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2015Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14259681 shares
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
15616452
CY2015Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
664000
CY2015Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1196817
CY2015Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
85714
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18381341
CY2015Q2 us-gaap Liabilities
Liabilities
2610354
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18226806
CY2015Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
425893
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
1426
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
60000
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1479034
CY2015Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
41427
CY2015Q2 us-gaap Indefinite Lived Contractual Rights
IndefiniteLivedContractualRights
711000
CY2015Q2 us-gaap Assets
Assets
18226806
CY2015Q2 us-gaap Inventory Net
InventoryNet
39442
CY2015Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
10142947
CY2015Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
157058
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29706
CY2015Q2 us-gaap Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock
ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock
5000000
CY2015Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
4886
CY2015Q2 us-gaap Indefinite Lived Trade Names
IndefiniteLivedTradeNames
79000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
8083859
CY2015Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
628776
CY2015Q2 us-gaap Goodwill
Goodwill
74000
CY2015Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
370888
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7353061
CY2015Q2 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
41427
CY2015Q2 aytu Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price
ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice
4.53
CY2015Q2 aytu Share Based Compensation Share Warrants Outstanding
ShareBasedCompensationShareWarrantsOutstanding
102613 shares
CY2015Q2 aytu Core And Developed Technology Net
CoreAndDevelopedTechnologyNet
780125
CY2015Q2 aytu Accrued Compensation Current
AccruedCompensationCurrent
196503
CY2015Q2 aytu Indefinite Lived Intangible Asset In Process Research And Development
IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment
7500000
CY2015Q2 aytu Prepaid Research And Development Related Party
PrepaidResearchAndDevelopmentRelatedParty
121983
CY2015Q2 aytu Prepaid Research And Development Related Party Noncurrent
PrepaidResearchAndDevelopmentRelatedPartyNoncurrent
335454
CY2015Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
12.174 pure
CY2015Q3 aytu Management Fee Payable Per Month
ManagementFeePayablePerMonth
30000
CY2015 aytu Class Of Warrant Or Rights Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm
P2Y11M1D
CY2014Q3 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2188075
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7901426 shares
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-2105061
CY2014Q3 us-gaap Sales Revenue Net
SalesRevenueNet
6000
CY2014Q3 us-gaap Revenues
Revenues
27583
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2091669
CY2014Q3 us-gaap Licenses Revenue
LicensesRevenue
21429
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-37302
CY2014Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-515107
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2128971
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-23910
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
202011
CY2014Q3 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-21429
CY2014Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
19000
CY2014Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1588075
CY2014Q3 us-gaap Interest Expense
InterestExpense
37302
CY2014Q3 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
600000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
933753
CY2014Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-23909
CY2014Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-136188
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
202000
CY2014Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1131276
CY2014Q3 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
600000
CY2014Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
37375
CY2014Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
24582
CY2014Q3 us-gaap Other Labor Related Expenses
OtherLaborRelatedExpenses
253000
CY2014Q3 us-gaap Cost Of Revenue
CostOfRevenue
225
CY2014Q3 aytu Research And Development Related Party
ResearchAndDevelopmentRelatedParty
53998
CY2014Q3 aytu Increase Decrease Accounts Payable Related Party Current
IncreaseDecreaseAccountsPayableRelatedPartyCurrent
-561059
CY2014Q3 aytu Products And Services Revenue
ProductsAndServicesRevenue
6154
CY2014Q3 aytu Amortization Of Prepaid Research And Development Due To Related Parties
AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties
30496
CY2014Q3 aytu Increase Decrease In Prepaid Research And Development Due To Related Parties
IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties
-150000
CY2015Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q3 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2157160
CY2015Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q3 us-gaap Sale Of Stock Percentage Of Ownership After Transaction
SaleOfStockPercentageOfOwnershipAfterTransaction
0.815 pure
CY2015Q3 dei Amendment Flag
AmendmentFlag
false
CY2015Q3 us-gaap Conversion Of Stock Description
ConversionOfStockDescription
The number of shares of Company stock that these warrants will convert into is equal to 8% of the gross number of shares of the Company stock issuable upon conversion of the Notes issued to investors introduced to the Company by the private placement agents pursuant to the private placement memorandum. The exercise price will be the lowest conversion price per share at which the Notes are converted into Company common stock. The warrants have a term of five years from August 31, 2015.
CY2015Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3554
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-2276188
CY2015Q3 us-gaap Sales Revenue Net
SalesRevenueNet
466000
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2015Q3 dei Document Type
DocumentType
10-Q
CY2015Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001385818
CY2015Q3 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2015Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On June 8, 2015, in connection with the reincorporation as a Delaware corporation, the Company effected a reverse stock split in which each common stock holder received one share of common stock for each every 12.174 shares then outstanding (the "Reverse Stock Split").
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P3Y6M18D
CY2015Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2015Q3 dei Entity Registrant Name
EntityRegistrantName
AYTU BIOSCIENCE, INC.
CY2015Q3 dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
CY2015Q3 dei Trading Symbol
TradingSymbol
AYTU
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14259681 shares
CY2015Q3 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y
CY2015Q3 us-gaap Revenues
Revenues
487385
CY2015Q3 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-11379
CY2015Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
68322
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2163063
CY2015Q3 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
454638
CY2015Q3 us-gaap Licenses Revenue
LicensesRevenue
21429
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-113125
CY2015Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10872
CY2015Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-10357
CY2015Q3 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
298322
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2276188
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015Q3 us-gaap Share Based Compensation
ShareBasedCompensation
68322
CY2015Q3 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-21428
CY2015Q3 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
5175000
CY2015Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
18000
CY2015Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2715964
CY2015Q3 us-gaap Interest Expense
InterestExpense
113125
CY2015Q3 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-3554
CY2015Q3 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4876678
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
855874
CY2015Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2015Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
0
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
68000
CY2015Q3 us-gaap Debt Issuance Costs
DebtIssuanceCosts
20000
CY2015Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1709251
CY2015Q3 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
57637
CY2015Q3 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
0
CY2015Q3 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
102931
CY2015Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
128921
CY2015Q3 us-gaap Other Labor Related Expenses
OtherLaborRelatedExpenses
264000
CY2015Q3 us-gaap Cost Of Revenue
CostOfRevenue
37325
CY2015Q3 aytu Research And Development Related Party
ResearchAndDevelopmentRelatedParty
47998
CY2015Q3 aytu Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
420538
CY2015Q3 aytu Increase Decrease Accounts Payable Related Party Current
IncreaseDecreaseAccountsPayableRelatedPartyCurrent
0
CY2015Q3 aytu Products And Services Revenue
ProductsAndServicesRevenue
465956
CY2015Q3 aytu Unrecognized Share Based Compensation Expenses
UnrecognizedShareBasedCompensationExpenses
10000
CY2015Q3 aytu Class Of Warrant Term
ClassOfWarrantTerm
P5Y
CY2015Q3 aytu Amortization Of Prepaid Research And Development Due To Related Parties
AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties
30496
CY2015Q3 aytu Increase Decrease In Prepaid Research And Development Due To Related Parties
IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties
0
CY2015Q3 aytu Class Of Warrant Or Rights Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm
P2Y11M1D
CY2015Q3 aytu Placement Agents Cash Fee Percentage
PlacementAgentsCashFeePercentage
0.08 pure

Files In Submission

Name View Source Status
0001193125-15-370153-index-headers.html Edgar Link pending
0001193125-15-370153-index.html Edgar Link pending
0001193125-15-370153.txt Edgar Link pending
0001193125-15-370153-xbrl.zip Edgar Link pending
aytu-20150930.xml Edgar Link completed
aytu-20150930.xsd Edgar Link pending
aytu-20150930_cal.xml Edgar Link unprocessable
aytu-20150930_def.xml Edgar Link unprocessable
aytu-20150930_lab.xml Edgar Link unprocessable
aytu-20150930_pre.xml Edgar Link unprocessable
d99194d10q.htm Edgar Link pending
d99194dex101.htm Edgar Link pending
d99194dex311.htm Edgar Link pending
d99194dex312.htm Edgar Link pending
d99194dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending